Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin in Non-Myeloablative Allo-Transplant for R/R CD20+ NHL
NCT01811368Phase 2Unknown
- Start
- Mar 2013
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in non-Hodgkin lymphoma (NHL). Status: unknown.
02
Drugs
ibritumomab tiuxetan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01811368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01811368.